BACKGROUND Nucleos(t)ide analogues reduce the incidence of hepatitis B virus (HBV) reactivation in cancer patients undergoing systemic cytotoxic chemotherapy but the experience of solid tumors remains limited. Aims. The aim of this study was to compare the efficacy of entecavir and lamivudine in the prophylaxis of HBV reactivation in solid tumor patients undergoing systemic cytotoxic chemothera...

There are few clinical data on the combination abacavir/lamivudine plus raltegravir. We compared the outcomes of patients from the SPIRAL trial receiving either abacavir/lamivudine or tenofovir/emtricitabine at baseline who had taken at least one dose of either raltegravir or ritonavir-boosted protease inhibitors. For the purpose of this analysis, treatment failure was defined as virological fa...

Lamivudine has been shown to be effective in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, but its long-term efficacy and the rate of resistant mutations in patients with HBeAg-negative chronic hepatitis B is less clear. Twenty-nine patients with HBeAg-negative chronic hepatitis B, who have received lamivudine for at least 1 year were studied to determine the antivir...

Introduction. Lamivudine is a nucleoside reverse transcriptase inhibitor antiretroviral agent used in the treatment of human immunodeficiency virus type 1 infection. This study was to investigate the effects of coadministration of neurovite and lamivudine on the histomorphology of the cerebellum of Wistar rats. Materials and Methods. Twenty Wistar rats were divided equally into four groups. Gro...

Lamivudine is a major drug approved for treatment of chronic hepatitis B virus (HBV) infection. Emergence of drug-resistant mutants with amino acid substitutions in the YMDD motif is a well-documented problem during long-term lamivudine therapy. Here we report a novel lamivudine-resistant strain of HBV with an intact YMDD motif, which included an amino acid substitution, rtA181T, in the reverse...

BACKGROUND/AIMS Complex mutants may be selected under sequential anti-VHB pressures. We analyzed the genotypic and phenotypic evolution of the viral quasi-species of a patient who developed resistance to entecavir following lamivudine breakthrough. METHODS The polymerase gene was amplified, cloned and sequenced at different time points. Hepatoma cell lines were transfected to compare the repl...

conclusions although the patients carrying m204i mutation were more likely to show lack of responses to lam therapy, lam replacing by other nucleoside/tide analogs plus hbig maybe still effective in decreasing hepatitis b recurrence after liver transplantation. however, it is suggested that drug resistance test should be considered by clinicians during therapeutic management to avoid the follow...

BACKGROUND Sequential monotherapies of nucleotide analogs used in chronic hepatitis B treatment can lead to the selection of a resistance mutation to each antiviral drug. CASE PRESENTATION A patient with chronic hepatitis B was successively treated with lamivudine monotherapy, lamivudine-adefovir dual therapy, adefovir monotherapy and again with an adefovir-lamivudine dual therapy. Lamivudine...

ABACAVIR+LAMIVUDINE+ZIDOVUDINE (TRIZIVIR, TZV) ABACAVIR+DOLUTEGRAVIR+LAMIVUDINE (TRIUMEQ, TRI) ADEFOVIR DIPIVOXIL (HEPSERA, ADV) AMPRENAVIR (AGENERASE, APV) (AGENERASE NO LONGER MANUFACTURED AS OF 2007) ATAZANAVIR (REYATAZ, ATV) ATAZANAVIR+COBICISTAT (EVOTAZ, EVO) COBICISTAT (TYBOST, COBI) DARUNAVIR (PREZISTA, DRV) DARUNAVIR+COBICISTAT (PREZCOBIXTM, REZOLSTATM, PCX) DELAVIRDINE MESYLATE (RESCRI...

The development of resistant hepatitis B virus (HBV) strains during lamivudine treatment has been described repeatedly. To investigate whether the development of such resistant HBV strains can be predicted in an early phase of therapy, the HBV loads of 11 renal transplantation patients were screened at 3-month intervals by a quantitative HBV polymerase chain reaction (PCR) assay. Lamivudine res...